Designed for routine screening labs

Swedish design for quick and easy procedure — no liquid-handling equipment needed.

Minimized hands-on time thanks to pre-filled and ready-to-use reagent plates.

The use of pre-filled reagent plates eliminates the need for a separate clean room for MasterMix preparation.

Newborn screening followed by an early diagnosis of SMA allows for pre-symptomatic treatment, significantly enhancing the effectiveness of therapies. 

This proactive approach greatly increases the likelihood that a child will develop without disabilities. In contrast, diagnosing SMA based on symptoms often leads to lifelong physical disability. 

Newborn screening for X-linked Agammaglobulinemia (XLA) can detect the lack of KRECs within a few days after birth, facilitating an earlier diagnosis for patients with XLA and earlier initiation of treatment. 

The non-invasive test from just a single blood spot sample, allows to screen for multiple conditions at once, including SCID, SMA, and XLA, ensuring that affected newborns receive early interventions that can drastically improve their quality of life.

Severe Combined Immunodeficiency, or SCID, causes major abnormalities of the immune system, leaving newborns unable to fight infections effectively.